

Executive Corridor
Darlington Memorial Hospital
Hollyhurst Road
Darlington
DL3 6HX
Switchboard Tel: 01325 38 0100
Foundation Trust Office: 01325 74 3625
Corporate Records Office: 01325 74 3700

Request for Information Reference: 06.19.23

Direct line: 01325 743700
Email: cdda-tr.cddftfoi@nhs.net

Email only

10 July 2019

Freedom of Information Act 2000 – Request for Information

Thank you for your request for information received on 12 June 2019 in relation to the County Durham and Darlington NHS Foundation Trust (Trust). We are dealing with your request under the provisions of the Freedom of Information Act 2000.

You requested information regarding cancer treatments. Specifically you requested information as follows:

1. Does your Trust treat adult multiple myeloma [MM]? If you refer your multiple myeloma patients to another centre, please state which?

Answer: Yes.

2. If yes, then how many MM patients, have been treated in the past 6 months with the following;

- ***Bortezomib [Velcade]***
- ***Carfilzomib [Kyprolis]***
- ***Ixazomib [Ninlaro]***
- ***Lenalidomide [Revlimid]***
- ***Daratumumab [Darzalex]***
- ***Melphalan, prednisolone and thalidomide (known as MPT)***
- ***Cyclophosphamide, thalidomide and dexamethasone (known as CTD)***
- ***Pomalidomide [Imnovid]***

Answer:

Bortezomib [Velcade]	7
Carfilzomib [Kyprolis]	0
Ixazomib [Ninlaro]	0

Lenalidomide [Revlimid]	29
Daratumumab [Darzalex]	8
Melphalan, prednisolone and thalidomide (known as MPT)	1
Cyclophosphamide, thalidomide and dexamethasone (known as CTD)	21
Pomalidomide [Imnovid]	1

3. If you are able to split by therapy line for question 2, please indicate the number of patients above being treated, 1st line and 2nd line?

Answer: The Trust is unable to split this information.

4. Does your Trust treat adult/paediatric primary immune thrombocytopenia patients [ITP]? If you refer your adult/paediatric primary immune thrombocytopenia patients to another centre, please state which?

Answer: Yes; some complex paediatric patients may be referred to the Children's Haematology Unit at the Royal Victoria Infirmary, Newcastle-Upon-Tyne.

5. If yes, then of the treated adult/paediatric primary immune thrombocytopenia patients, how many are on the following;

- **Eltrombopag [Revolade]**
- **Romiplostim [Nplate]**

Answer: Between January and June 2019, the Trust had 12 patients with ITP receiving treatment with eltrombopag, and 4 with romiplostim.

6. At what line of treatment would you currently use a Thrombopoietin Receptor Agonist [TPO] (Eltrombopag [Revolade], Romiplostim [Nplate]) in an immune thrombocytopenia purpura [ITP] patient?

- **1st**
- **2nd**
- **3rd**
- **4th**
- **Unknown**

Answer: Used in the 2nd or 3rd line of treatment depending on individual patient factors.

7. Do you treat patients with a Thrombopoietin Receptor Agonist TPO for the following diseases:

7a. Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor

preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

- **Eltrombopag [Revolade]**
- **Romiplostim [Nplate]**

Answer: The Trust does not treat hepatitis C at present.

7b.Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation?

- **Eltrombopag [Revolade]:** Yes
- **Romiplostim [Nplate]:** Yes

7c. Chemotherapy induced thrombocytopenia (CIT):

- **Eltrombopag [Revolade]:** No
- **Romiplostim [Nplate]:** No

7d. myelodysplastic syndromes (MDS):

- **Eltrombopag [Revolade]:** No
- **Romiplostim [Nplate]:** No

8. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?

Answer: 44.

9. If possible how many CLL patients treated were new to therapy in the past 3 months?

Answer: 4 patients on cycle 1 in the period 21 April – 21 June 2019.

10. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;

- **Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR)**
- **Bendamustine and rituximab (known as BR)**
- **Ibrutinib [Imbruvica]**
- **Chlorambucil**
- **Venetoclax**
- **Obinutuzumab**
- **Idelalisib**
- **Fludarabine and rituximab (known as FR)**
- **High-dose prednisone and rituximab**
- **Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)**

- ***Alemtuzumab (Campath) with rituximab***

Answer:

Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR)	0
Bendamustine and rituximab (known as BR)	4
Ibrutinib [Imbruvica]	26
Chlorambucil	3
Venetoclax	0
Obinutuzumab	0
Idelalisib	0
Fludarabine and rituximab (known as FR)	0
High-dose prednisone and rituximab	0
Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)	0
Alemtuzumab (Campath) with rituximab	0

Please note, there were also 7 patients on Obinutuzumab + Chlorambucil combination therapy.

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log. Therefore, a version of our response which will protect your anonymity will be posted on the County Durham and Darlington NHS Foundation Trust website.

If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me on the above telephone number or at the above address.

If you are unhappy with the way your request for information has been handled, you can request a review by writing to:

The Chief Executive
County Durham & Darlington NHS Foundation Trust
Darlington Memorial Hospital
Hollyhurst Road
Darlington, DL3 6HX

If, you remain dissatisfied with the handling of your request or complaint, you have a right to appeal to the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House

Water Lane
Wilmslow
Cheshire
SK9 5AF

Telephone: 0303 123 1113
Website: www.ico.gov.uk.

There is no charge for making an appeal.

Yours sincerely

Joanna Tyrrell
Freedom of Information Officer